Pdl Biopharma Inc (PDLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2005 | 06-2005 | 03-2005 | 12-2004 | 09-2004 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 181,766 | 36,667 | 15,077 | 91,395 | 130,900 |
| Marketable Securities | 150,912 | 150,942 | 165,234 | 140,579 | 288,209 |
| Receivables | 17,906 | 16,941 | N/A | N/A | N/A |
| Inventories | 18,688 | 18,142 | 19,837 | N/A | N/A |
| Income taxes - deferred | 10,100 | N/A | N/A | N/A | N/A |
| Other current assets | 0 | 10,647 | 18,702 | 0 | 5,911 |
| TOTAL | $390,049 | $233,339 | $218,850 | $241,724 | $425,020 |
| Non-Current Assets | |||||
| PPE Net | 261,698 | 256,443 | 251,990 | 238,077 | 227,027 |
| Investments And Advances | 0 | 3,369 | 3,355 | 165,106 | 6,688 |
| Intangibles | 481,624 | 517,255 | 529,645 | 31,309 | 31,972 |
| Other Non-Current Assets | 43,606 | 44,490 | 44,937 | 37,516 | 37,073 |
| TOTAL | $786,928 | $821,557 | $829,927 | $472,008 | $302,760 |
| Total Assets | $1,176,977 | $1,054,896 | $1,048,777 | $713,732 | $727,780 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | 544 | N/A |
| Accounts payable and accrued liabilities | 11,000 | 6,949 | 8,175 | 4,921 | 4,444 |
| Accrued Expenses | 23,137 | 21,923 | 18,402 | 6,977 | 8,969 |
| Other current liabilities | 697 | 752 | 825 | N/A | 1,048 |
| TOTAL | $117,618 | $69,756 | $70,575 | $43,454 | $46,390 |
| Non-Current Liabilities | |||||
| Long Term Debt | 7,387 | 7,549 | 7,289 | 7,770 | 7,675 |
| Deferred Revenues | 56,675 | 16,332 | 16,317 | 17,389 | 17,760 |
| Other Non-Current Liabilities | 499,998 | 499,998 | 500,370 | 249,998 | 249,998 |
| TOTAL | $507,385 | $507,547 | $507,659 | $257,768 | $257,673 |
| Total Liabilities | $625,003 | $577,303 | $578,234 | $301,222 | $304,063 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 112,837 | 107,104 | 106,019 | 96,070 | 95,506 |
| Common Shares | 1,125 | 1,068 | 1,059 | 959 | 954 |
| Retained earnings | -400,197 | -360,847 | -357,427 | -273,532 | -258,950 |
| Other shareholders' equity | -4,273 | -1,676 | -2,491 | -1,219 | -397 |
| TOTAL | $551,974 | $477,593 | $470,543 | $412,510 | $423,717 |
| Total Liabilities And Equity | $1,176,977 | $1,054,896 | $1,048,777 | $713,732 | $727,780 |